Capricor climbs as FDA clears path for resubmission of cell therapy application

Shares of therapy developer Capricor Therapeutics CAPR.O rise 1.6% to $6.29 premarket

Co says it has completed a key clinical trial for its muscle disorder therapy and expects to share results by Q4

Co says the U.S. FDA has agreed that data from the trial could be used to support its marketing application for the cell therapy, Deramiocel

Deramiocel is being developed to treat Duchenne muscular dystrophy, a rare and progressive genetic disorder that causes muscle degeneration and weakness

In July, the agency declined to approve Deramiocel and requested more data

Capricor says it has addressed all manufacturing-related issues

As of last close, stock down 55% YTD